Sangamo Therapeutics Reports 77.6% Revenue Decline in Q1 2026

Sangamo Therapeutics, Inc. reported a significant decline in revenue for the first quarter of 2026, generating $1.4 million compared to $6.4 million in the same period of 2025, marking a decrease of approximately 77.6%. This drop was primarily attributed to the absence of revenue from a collaboration agreement with Pfizer, which contributed $5 million in the previous year. Operating expenses also decreased to $33.4 million from $36.1 million, driven by a reduction in general and administrative costs, which fell by 32% to $6.8 million. Despite these reductions, the company recorded a net loss of $31 million, slightly higher than the $30.6 million loss reported in the prior year.

In terms of financial position, Sangamo's cash and cash equivalents increased to $27.6 million as of March 31, 2026, up from $20.9 million at the end of 2025. The company has been actively pursuing additional funding through various means, including an at-the-market offering program, which has approximately $129.5 million remaining available. During the first quarter, Sangamo raised about $26.7 million through financing activities, including proceeds from the issuance of common stock and pre-funded warrants.

Strategically, Sangamo is focusing on its neurology programs, particularly the development of epigenetic regulation therapies and engineered adeno-associated virus (AAV) capsids. The company is currently engaged in clinical trials for its Fabry disease program, with a rolling submission of a Biologics License Application (BLA) to the FDA expected to continue into the summer of 2026, contingent on securing adequate funding. The company is also exploring partnerships to advance its Fabry disease program, although discussions are still in early stages.

Operationally, Sangamo has activated six clinical sites for its Phase 1/2 STAND study evaluating ST-503, an investigational treatment for small fiber neuropathy. The company is also in the process of conducting a Good Laboratory Practice toxicology study for ST-506, aimed at treating prion disease. However, the company faces substantial challenges, including a history of significant losses and the need for additional capital to continue operations. Management has expressed substantial doubt about the company's ability to continue as a going concern without securing further funding in the near term.

Looking ahead, Sangamo's ability to sustain operations and advance its product candidates is heavily reliant on securing substantial additional capital. The company is actively seeking collaborations and other financing options to support its ongoing research and development efforts. If adequate funding is not obtained, Sangamo may be forced to scale back operations significantly or consider other strategic alternatives, including potential bankruptcy.